- Home
- IAS vs JANX Comparison
IAS vs JANX Comparison
Compare IAS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- JANX
- Stock Information
- Founded
- IAS 2009
- JANX 2017
- Country
- IAS United States
- JANX United States
- Employees
- IAS N/A
- JANX N/A
- Industry
- IAS Computer Software: Programming Data Processing
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- IAS Technology
- JANX Health Care
- Exchange
- IAS Nasdaq
- JANX Nasdaq
- Market Cap
- IAS 1.3B
- JANX 1.6B
- IPO Year
- IAS 2021
- JANX 2021
- Fundamental
- Price
- IAS $7.94
- JANX $23.60
- Analyst Decision
- IAS Buy
- JANX Strong Buy
- Analyst Count
- IAS 11
- JANX 7
- Target Price
- IAS $13.55
- JANX $94.29
- AVG Volume (30 Days)
- IAS 1.0M
- JANX 808.2K
- Earning Date
- IAS 07-31-2025
- JANX 08-06-2025
- Dividend Yield
- IAS N/A
- JANX N/A
- EPS Growth
- IAS 2607.38
- JANX N/A
- EPS
- IAS 0.29
- JANX N/A
- Revenue
- IAS $549,637,000.00
- JANX $9,336,000.00
- Revenue This Year
- IAS $13.39
- JANX N/A
- Revenue Next Year
- IAS $11.41
- JANX $1,470.82
- P/E Ratio
- IAS $28.62
- JANX N/A
- Revenue Growth
- IAS 13.84
- JANX 28.12
- 52 Week Low
- IAS $6.26
- JANX $22.48
- 52 Week High
- IAS $13.62
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- IAS 46.53
- JANX 41.60
- Support Level
- IAS $8.02
- JANX $24.45
- Resistance Level
- IAS $8.41
- JANX $27.28
- Average True Range (ATR)
- IAS 0.22
- JANX 1.35
- MACD
- IAS -0.03
- JANX -0.09
- Stochastic Oscillator
- IAS 14.05
- JANX 22.20
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.